Manufacturers announce positive results for US expanded access use of aviptadil in patients with critical COVID-19 and severe comorbidity

Manufacturers report that 175 patients have now been entered into an Expanded Access Protocol with aviptadil in the United States, and that 72% have survived to day 28. This survival rate is comparable to the recently reported interim results of an open label study.

Source:

Biospace Inc.